| __timestamp | Agios Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 1513000 |
| Thursday, January 1, 2015 | 141827000 | 12573000 |
| Friday, January 1, 2016 | 220163000 | 42238000 |
| Sunday, January 1, 2017 | 292681000 | 69800000 |
| Monday, January 1, 2018 | 1397000 | 113773000 |
| Tuesday, January 1, 2019 | 1317000 | 179362000 |
| Wednesday, January 1, 2020 | 2805000 | 269407000 |
| Friday, January 1, 2021 | 18777000 | 17953000 |
| Saturday, January 1, 2022 | 1704000 | 110250000 |
| Sunday, January 1, 2023 | 9504000 | 130250000 |
| Monday, January 1, 2024 | 4165000 | -2314000 |
Infusing magic into the data realm
In the competitive world of biotechnology, cost efficiency can be a decisive factor for success. This analysis compares the cost of revenue efficiency between CRISPR Therapeutics AG and Agios Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, CRISPR Therapeutics AG demonstrated a remarkable upward trend, with its cost of revenue increasing by over 8,500% from 2014 to 2023. In contrast, Agios Pharmaceuticals, Inc. experienced a more volatile journey, peaking in 2017 before a significant decline. By 2023, CRISPR Therapeutics AG's cost of revenue was approximately 13 times higher than Agios Pharmaceuticals, Inc. This stark contrast highlights CRISPR's aggressive growth strategy and its potential impact on the biotech landscape. As the industry evolves, understanding these financial dynamics is crucial for investors and stakeholders alike.
Zoetis Inc. vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Agios Pharmaceuticals, Inc.
Bio-Techne Corporation vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs CRISPR Therapeutics AG
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Agios Pharmaceuticals, Inc.
CRISPR Therapeutics AG vs MorphoSys AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: CRISPR Therapeutics AG vs Evotec SE
Comparing Cost of Revenue Efficiency: CRISPR Therapeutics AG vs Xencor, Inc.
CRISPR Therapeutics AG vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Agios Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Efficiency in Cost of Revenue Explored